Last updated on April 19, 2014 at 18:42 EDT

Pharmalink AB Elects Anders Wiklund as Chairman and Appoints Elisabeth Lindner to its Board of Directors

November 14, 2011

STOCKHOLM, November 14, 2011 /PRNewswire/ –

Pharmalink AB, is pleased to announce today that Anders Wiklund has been
elected to serve as Chairman of the Board. In addition, the Board is
strengthened by former CEO and President of Diamyd, Elisabeth Lindner who
joins the Board of Directors. Pharmalink’s founder and former chairman,
Bengt Julander, and Lennart Hansson of Industrifonden, remain on the Board
as a Non-Executive Directors.

Anders Wiklund has gained a wealth of business and corporate development
experience in the biotechnology and pharmaceutical industry from a career in
Europe and the US spanning 40 years. He spent 29 years with the Kabi and
Pharmacia group of companies, where he held a number of different positions,
such as Managing Director of KabiVitrum in the UK, President of KabiVitrum
International in Sweden, President and CEO of KabiVitrum and KabiPharmacia
in the USA. Mr. Wiklund also currently serves on the boards of QuatRx Inc,
EffRx SA, Clavis Pharma AS and Life Medical AB.

Ms. Elisabeth Lindner is one of Sweden’s most experienced experts within
the biopharmaceutical industry, with more than 25 years experience in senior
management roles at Octapharma AB, Pharmacia Corporation and most recently
as President and Chief Executive Officer at Diamyd Medical AB. Ms. Lindner
is a Director at BioInvent International AB and Karo Bio AB, and serves as
Director of the Royal Swedish Academy of Engineering Science. She holds an
MSc from Stockholm University and an M.B.A from Uppsala University.

“With Anders taking on the Chairman’s role and Elisabeth joining the
Board, Pharmalink is positioned for the next stage of development,” says
Johan Haggblad, Managing Director of Pharmalink. “Nefecon and Busulipo are
two highly promising product candidates under evaluation. Anders’s and
Elisabeth’s exceptional industry experience will be invaluable in ensuring
we realize value for Pharmalink and for patients with significant unmet
medical need.”

About Pharmalink

Pharmalink is a Swedish specialty pharma company developing high value
products for niche indications. Pharmalink draws on its extensive experience
of pharmaceutical product development and the excellence of medical science
in Sweden to identify and progress products that address significant unmet
medical needs. Pharmalink has introduced more than 15 pharmaceutical
products to the market. Using a repurposing and reformulation strategy,
Pharmalink minimizes the risk of product development. The Company’s strategy
is to apply its expertise to drive drug development and commercialize with
partners. Pharmalink currently has two clinical phase projects under
development, Nefecon(R) and BusulipoTM, and is actively in-licensing
promising new projects to add to its pipeline. Visit
http://www.pharmalink.se for further information.

        For further information, please contact:

        Johan Haggblad, Managing Director, +46(0)70-668-0644
        Email:  johan.haggblad@pharmalink.se


        Citigate Dewe Rogerson:
        Chris Gardner/Nina Enegren, +44-207-638-9571

SOURCE Pharmalink

Source: PR Newswire